Literature DB >> 9345448

The Brief Repeatable Battery of Neuropsychological Tests for Multiple Sclerosis: a preliminary serial study.

C T Bever1, L Grattan, H S Panitch, K P Johnson.   

Abstract

The Brief Repeatable Battery of Neuropsychological Tests (BRB-N) for MS consisting of the selective reminding, 10/36 spatial recall, symbol digit modalities, paced auditory serial addition (PASAT) and word list generation tests is a sensitive measure of early cognitive impairment in MS patients. We administered it to 19 chronic stable MS patients every 60 days for 120 days to examine variability. The mean coefficient of variation for the tests ranged from 18% to 22%. A significant practice effect was seen in the PASAT results (P < 0.05) using the Wilcoxon signed rank test. These results suggest that cognitive fluctuations analogous to motor fluctuations may occur in MS patients and that the BRB-N may be useful in clinical trials of agents expected to alter cognitive function in MS patients if test-retest variability and practice effects are taken into account. Further study is warranted.

Entities:  

Mesh:

Year:  1995        PMID: 9345448     DOI: 10.1177/135245859500100306

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  30 in total

Review 1.  Physical activity and cognitive function in adults with multiple sclerosis: an integrative review.

Authors:  Janet D Morrison; Lori Mayer
Journal:  Disabil Rehabil       Date:  2016-10-20       Impact factor: 3.033

2.  Normative values of the Rao's Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education.

Authors:  Fabrizia Falco; Marcello Moccia; Alessandro Chiodi; Antonio Carotenuto; Angelo D'Amelio; Laura Rosa; Kyrie Piscopo; Andrea Falco; Teresa Costabile; Francesca Lauro; Vincenzo Brescia Morra; Roberta Lanzillo
Journal:  Neurol Sci       Date:  2019-01-15       Impact factor: 3.307

3.  Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.

Authors:  Luis Hernandez; Malinda O'Donnell; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

4.  Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis.

Authors:  M S A Deloire; E Salort; M Bonnet; Y Arimone; M Boudineau; H Amieva; B Barroso; J-C Ouallet; C Pachai; E Galliaud; K G Petry; V Dousset; C Fabrigoule; B Brochet
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-04       Impact factor: 10.154

5.  7T MPFLAIR versus MP2RAGE for Quantifying Lesion Volume in Multiple Sclerosis.

Authors:  Margaret Spini; Seongjin Choi; Daniel M Harrison
Journal:  J Neuroimaging       Date:  2020-06-22       Impact factor: 2.486

Review 6.  Risk factors for and management of cognitive dysfunction in multiple sclerosis.

Authors:  Ralph H B Benedict; Robert Zivadinov
Journal:  Nat Rev Neurol       Date:  2011-05-10       Impact factor: 42.937

7.  Leptomeningeal Enhancement at 7T in Multiple Sclerosis: Frequency, Morphology, and Relationship to Cortical Volume.

Authors:  Daniel M Harrison; Kevin Y Wang; Julie Fiol; Kerry Naunton; Walter Royal; Jun Hua; Izlem Izbudak
Journal:  J Neuroimaging       Date:  2017-05-02       Impact factor: 2.486

8.  Cognitive impairment in probable multiple sclerosis.

Authors:  A Achiron; Y Barak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

9.  Variations in functioning and disability in multiple sclerosis. A two-year prospective study.

Authors:  Charlotte Ytterberg; Sverker Johansson; Magnus Andersson; Lotta Widén Holmqvist; Lena von Koch
Journal:  J Neurol       Date:  2008-06-17       Impact factor: 4.849

10.  [Normalization of the Brief Repeatable Battery of Neuropsychological tests (BRB-N) for German-speaking regions. Application in relapsing-remitting and secondary progressive multiple sclerosis patients].

Authors:  P Scherer; K Baum; H Bauer; H Göhler; C Miltenburger
Journal:  Nervenarzt       Date:  2004-10       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.